Introduction/Background Randomized trials established the clinical benefit of PD-1-inhibitors in recurrent/metastatic cervical cancer (CC). However, this benefit seems to be restricted mainly to PD-L1-positiv CC. The purpose of this study was to compare the PD-L1-status in primary CC with a paired sample at the time of recurrent/metastatic disease.
Methodology PD-L1-scoring was analyzed by immunohistochemistry (Ventana PD-L1 (SP263) in archived tumor tissue of primary CC and paired recurrent/metastatic CC (n= 24). PD-L1-positivity was defined as CPS (combined positive score) ≥1.
Results 50% (12/24) of patients were in FIGO stage IB1-IIA2 at primary diagnosis and the majority had squamous cell histology (87.5%; 21/24). Median PFS was 8.9 (95% CI: 7.8–10.0) months.PD-L1-CPS ≥1 was found in 96% (23/24) of primary and 92% (22/24) of paired recurrent/metastatic CC. The median CPS was 22 (range 0–80) in primary and 20 (range 0–90) in recurrent/metastatic CC. Correlation between primary and recurrent/metastatic CC was high (0.79). Only in one case a shift from a CPS-positive primary to CPS-negative relapsed disease was detected.
Conclusion Comparing PD-L1-status (CPS) between primary and recurrent/metastatic CC demonstrated a high concordance. Our data indicate, that PD-L1 testing in archival material from primary tumor is sufficient, if a fresh sample at relapse or of metastases is not available.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.